Loading
Max Wicha identified breast cancer stem cells and made them a therapeutic target.
Max S. Wicha is the Madeline and Sidney Forbes Professor of Oncology and Founding Director of the Rogel Cancer Center at the University of Michigan. He is known for identifying breast cancer stem cells and making them a therapeutic target, as co-author of the 2003 paper that isolated tumorigenic breast cancer cells. His selected paper reports the prospective identification of tumorigenic breast cancer cells. He founded Michigan's cancer centre and continues to study stem cell pathways such as IL-6/STAT3 and Notch in triple-negative and hormone receptor-positive breast cancer.
| Title | Journal | Year |
|---|---|---|
| Prospective identification of tumorigenic breast cancer cells | PNAS | 2003 |
Shares Al-Hajj 2003: prospective identification of tumorigenic breast cancer cells, Epithelial-mesenchymal transition & drug efflux, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares University of Michigan Rogel Cancer Center, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Epithelial-mesenchymal transition & drug efflux, HR-positive / HER2-negative breast cancer.
Shares Epithelial-mesenchymal transition & drug efflux, Triple-negative breast cancer (TNBC).
Shares Epithelial-mesenchymal transition & drug efflux, Triple-negative breast cancer (TNBC).
Shares Epithelial-mesenchymal transition & drug efflux, Triple-negative breast cancer (TNBC).
Shares Epithelial-mesenchymal transition & drug efflux, HR-positive / HER2-negative breast cancer.
Shares Epithelial-mesenchymal transition & drug efflux, Triple-negative breast cancer (TNBC).